BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 10945205)

  • 1. A single center's clinical experience with quadruple immunosuppression including ATG or IL2 antibodies and mycophenolate mofetil in simultaneous pancreas-kidney transplants.
    Hesse UJ; Troisi R; Jacobs B; Van Vlem B; de Hemptinne B; Van Holder R; Vermassen F; De Roose J; Lameire N
    Clin Transplant; 2000 Aug; 14(4 Pt 1):340-4. PubMed ID: 10945205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.
    Woodroffe R; Yao GL; Meads C; Bayliss S; Ready A; Raftery J; Taylor RS
    Health Technol Assess; 2005 May; 9(21):1-179, iii-iv. PubMed ID: 15899149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection.
    Sollinger H; Kaplan B; Pescovitz MD; Philosophe B; Roza A; Brayman K; Somberg K
    Transplantation; 2001 Dec; 72(12):1915-9. PubMed ID: 11773888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of single bolus ATG and Basiliximab as induction therapy in presensitized renal allograft recipients receiving tacrolimus-based immunosuppressive regimen.
    Yang SL; Wang D; Wu WZ; Lin WH; Xu TZ; Cai JQ; Tan JM
    Transpl Immunol; 2008 Jan; 18(3):281-5. PubMed ID: 18047938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
    Gruessner RW
    Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mycophenolate mofetil decreases rejection in simultaneous pancreas-kidney transplantation when combined with tacrolimus or cyclosporine.
    Stegall MD; Simon M; Wachs ME; Chan L; Nolan C; Kam I
    Transplantation; 1997 Dec; 64(12):1695-700. PubMed ID: 9422404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of a single-center experience with mycophenolate mofetil based immunosuppression in renal transplantation.
    Triemer HL; Pearson TC; Odom KL; Larsen CP
    Clin Transplant; 2000 Aug; 14(4 Pt 2):413-20. PubMed ID: 10946781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A study comparing mycophenolate mofetil to azathioprine in simultaneous pancreas-kidney transplantation.
    Odorico JS; Pirsch JD; Knechtle SJ; D'Alessandro AM; Sollinger HW
    Transplantation; 1998 Dec; 66(12):1751-9. PubMed ID: 9884272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rabbit-ATG or basiliximab induction for rapid steroid withdrawal after renal transplantation (Harmony): an open-label, multicentre, randomised controlled trial.
    Thomusch O; Wiesener M; Opgenoorth M; Pascher A; Woitas RP; Witzke O; Jaenigen B; Rentsch M; Wolters H; Rath T; Cingöz T; Benck U; Banas B; Hugo C
    Lancet; 2016 Dec; 388(10063):3006-3016. PubMed ID: 27871759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mycophenolate mofetil in pediatric renal transplantation: non-induction vs. induction with basiliximab.
    Ojogho O; Sahney S; Cutler D; Baron PW; Abdelhalim FM; James S; Zuppan C; Franco E; Concepcion W
    Pediatr Transplant; 2005 Feb; 9(1):80-3. PubMed ID: 15667617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early steroid withdrawal protocol with basiliximab, cyclosporine and mycophenolate mofetil in renal-transplant recipients.
    Kato Y; Tojimbara T; Iwadoh K; Koyama I; Nanmoku K; Kai K; Sannomiya A; Nakajima I; Fuchinoue S; Teraoka S
    Int Immunopharmacol; 2006 Dec; 6(13-14):1984-92. PubMed ID: 17161352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential protocols using basiliximab versus antithymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids.
    Mourad G; Rostaing L; Legendre C; Garrigue V; Thervet E; Durand D
    Transplantation; 2004 Aug; 78(4):584-90. PubMed ID: 15446319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction treatment with rabbit antithymocyte globulin versus basiliximab in renal transplant recipients with planned early steroid withdrawal.
    Martin ST; Roberts KL; Malek SK; Tullius SG; Vadivel N; De Serres S; Grafals M; Elsanjak A; Filkins BA; Chandraker A; Gabardi S
    Pharmacotherapy; 2011 Jun; 31(6):566-73. PubMed ID: 21923440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mycophenolate mofetil and tacrolimus as primary maintenance immunosuppression in simultaneous pancreas-kidney transplantation: initial experience in 50 consecutive cases.
    Kaufman DB; Leventhal JR; Stuart J; Abecassis MM; Fryer JP; Stuart FP
    Transplantation; 1999 Feb; 67(4):586-93. PubMed ID: 10071032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Basiliximab induction in renal transplantation: long-term outcome.
    Atlani M; Sharma RK; Gupta A
    Saudi J Kidney Dis Transpl; 2013 May; 24(3):473-9. PubMed ID: 23640617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Basiliximab: a review of its use as induction therapy in renal transplantation.
    Chapman TM; Keating GM
    Drugs; 2003; 63(24):2803-35. PubMed ID: 14664658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secondary effects of immunosuppressive drugs after simultaneous pancreas-kidney transplantation.
    Kuypers DR; Malaise J; Claes K; Evenepoel P; Maes B; Coosemans W; Pirenne J; Vanrenterghem Y;
    Nephrol Dial Transplant; 2005 May; 20 Suppl 2():ii33-9, ii62. PubMed ID: 15814548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved solitary pancreas transplant graft survival in the modern immunosuppressive era.
    Odorico JS; Becker YT; Groshek M; Werwinski C; Becker BN; Pirsch JD; Sollinger HW
    Cell Transplant; 2000; 9(6):919-27. PubMed ID: 11202579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triple immunosuppression with or without basiliximab in pediatric renal transplantation: acute rejection rates at one year.
    Duzova A; Buyan N; Bakkaloglu M; Dalgic A; Soylemezoglu O; Besbas N; Bakkaloglu A
    Transplant Proc; 2003 Dec; 35(8):2878-80. PubMed ID: 14697926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group.
    Sollinger HW
    Transplantation; 1995 Aug; 60(3):225-32. PubMed ID: 7645033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.